| Pembrolizumab cutaneous adverse events and their association with disease progression M Sanlorenzo, I Vujic, A Daud, A Algazi, M Gubens, SA Luna, K Lin, ... JAMA dermatology 151 (11), 1206-1212, 2015 | 431 | 2015 |
| EXO1 resection at G-quadruplex structures facilitates resolution and replication S Stroik, K Kurtz, K Lin, S Karachenets, CL Myers, AK Bielinsky, ... Nucleic acids research 48 (9), 4960-4975, 2020 | 31 | 2020 |
| The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma M Sanlorenzo, I Vujic, R Esteve-Puig, K Lai, M Vujic, K Lin, C Posch, ... Scientific reports 8 (1), 10902, 2018 | 22 | 2018 |
| Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome M Sanlorenzo, I Vujic, C Posch, J Ma, K Lin, K Lai, D Lee, M Vujic, ... Journal of proteomics 144, 140-147, 2016 | 17 | 2016 |
| Identification of inhibitors of the association of ZAP-70 with the T cell receptor by high-throughput screen PR Visperas, CG Wilson, JA Winger, Q Yan, K Lin, MR Arkin, A Weiss, ... SLAS DISCOVERY: Advancing Life Sciences R&D 22 (3), 324-331, 2017 | 13 | 2017 |
| Scalable CRISPR-Cas9 chemical genetic screens in non-transformed human cells K Lin, YC Chang, EMF de Velasco, K Wickman, CL Myers, AK Bielinsky STAR protocols 3 (4), 101675, 2022 | 3 | 2022 |
| RNF4 and USP7 cooperate in ubiquitin-regulated steps of DNA replication YC Chang, K Lin, RM Baxley, W Durrett, L Wang, O Stojkova, M Billmann, ... Open biology 13 (8), 230068, 2023 | 2 | 2023 |
| Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancer—a case report S Ghatak, K Lin, E Lou, AC Nelson Precision Cancer Medicine 3, 2020 | 2 | 2020 |
| Immunotherapy in melanoma, gastrointestinal (GI), and pulmonary malignancies AB Dillon, K Lin, A Kwong, S Ortiz AIMS public health 2 (1), 86, 2015 | 2 | 2015 |
| RNF4 prevents genomic instability caused by chronic DNA under-replication MK Oram, RM Baxley, EM Simon, K Lin, YC Chang, L Wang, CL Myers, ... DNA repair, 103646, 2024 | 1 | 2024 |
| 12621 Targeted Chemical-Genetic Screen Platform for Identifying Drug Modes-of-Action K Lin, M Billmann, H Ward, YC Chang, AK Bielinsky, CL Myers Journal of Clinical and Translational Science 5 (s1), 101-102, 2021 | 1 | 2021 |
| The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma V Feichtenschlager, L Chen, YJ Zheng, W Ho, M Sanlorenzo, I Vujic, ... Molecular Cancer 23 (1), 40, 2024 | | 2024 |
| A scalable platform for efficient CRISPR-Cas9 chemical-genetic screens of DNA damage-inducing compounds K Lin, YC Chang, M Billmann, HN Ward, K Le, AZ Hassan, U Bhojoo, ... Scientific Reports 14 (1), 2508, 2024 | | 2024 |
| Fanconi anemia-associated chromosomal radial formation is dependent on POLθ-mediated alternative end joining CB Rogers, RE Kram, K Lin, CL Myers, A Sobeck, EA Hendrickson, ... Cell reports 42 (5), 2023 | | 2023 |
| Abstract P2-17-01: Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair B Stefanovska, K Lin, B Troness, C Myers, R Harris Cancer Research 83 (5_Supplement), P2-17-01-P2-17-01, 2023 | | 2023 |
| LncRNA as potential target in drug-resistant melanomas R Esteve-Puig, M Sanlorenzo, I Vujic, K Lai, M Vujic, D Mould, K Lin, ... Cancer Research 77 (13_Supplement), 3493-3493, 2017 | | 2017 |
Sanlorenzo Martina MD, PhDDepartment of Medicine, Institute of Cancer Research, Medical University of ViennaVerified email at meduniwien.ac.at
